SLC13A3: A Drug Target and Potential Biomarker forfungal Infections

Target Name: SLC13A3

NCBI ID: G64849

SLC13A3

SLC13A3: A Drug Target and Potential Biomarker forfungal Infections

Sodium-dependent high affinity dicarboxylate transporter 3 (SLC13A3) is a protein that is expressed in various cell types, including fungi, bacteria, and eukaryotes. It is a transmembrane protein that is primarily localized to the endoplasmic reticulum (ER) and has been shown to play a role in the transport of various molecules, including drugs and toxins. One of the unique aspects of SLC13A3 is its ability to transport dicarboxylate, which is a type of molecule that is derived from amino acids that have been modified to include a carboxylic acid group.

The SLC13A3 protein is composed of 184 amino acids and has a calculated molecular mass of 21.1 kDa. It is expressed in various cell types, including fungi, bacteria, and eukaryotes, and is primarily localized to the ER. SLC13A3 is a monomer and has been shown to have a unique localization in the ER. It is also known to play a role in the transport of various molecules, including drugs and toxins.

One of the unique aspects of SLC13A3 is its ability to transport dicarboxylate, which is a type of molecule that is derived from amino acids that have been modified to include a carboxylic acid group. This ability is critical for the function of SLC13A3, as it allows the protein to play a role in the transport of various molecules that require dicarboxylation.

SLC13A3 has been shown to play a role in the transport of a variety of molecules, including drugs and toxins. For example, studies have shown that SLC13A3 is able to transport the drug Clindamycin, which is used to treat fungal infections such as Aspergillus flavus and Candida albicans. Clindamycin works by inhibiting the synthesis of ergosterol, which is a key component of fungal cell membranes. This inhibition allows the drug to kill off fungal infections.

Another study has also shown that SLC13A3 is able to transport the toxic compound TCEP (2,4,6-tri-(2-methylpropylamino)phenol), which is commonly used as a wood preservative. TCEP is able to cross the ER membrane and interact with SLC13A3, leading to the inhibition of cellular processes that are necessary for the survival of the fungal pathogen. This interaction between TCEP and SLC13A3 suggests that SLC13A3 may be a potential drug target for fungal infections.

In addition to its role in the transport of drugs and toxins, SLC13A3 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that SLC13A3 is able to regulate the levels of various molecules in the cell, including enzymes and signaling proteins. This regulation allows SLC13A3 to play a role in the control of cellular processes that are necessary for the survival of the cell.

Overall, SLC13A3 is a unique protein that is expressed in various cell types and has been shown to play a role in the transport of various molecules, including drugs and toxins. Its ability to transport dicarboxylate and its role in the regulation of cellular processes make it a potential drug target and biomarker for fungal infections. Further research is needed to fully understand the function of SLC13A3 and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 13 Member 3

Functions: High-affinity sodium-dicarboxylate cotransporter that accepts a range of substrates with 4-6 carbon atoms, such as the citric acid cycle intermediates succinate and alpha-ketoglutarate (2-oxoglutarate), as well as other compounds including N-acetyl-L-aspartate (PubMed:10794676, PubMed:10992006, PubMed:15561973, PubMed:17426067, PubMed:17356845, PubMed:24247155, PubMed:30635937). Transports the dicarboxylate into the cell with a probable stoichiometry of 3 Na(+) for 1 divalent dicarboxylate, rendering the process electrogenic (PubMed:10794676, PubMed:10992006). Can transport citrate in a Na(+)-dependent manner, recognizing the divalent form of citrate rather than the trivalent form which is normally found in blood (PubMed:10794676)

The "SLC13A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC13A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets